Terms: = Prostate cancer AND CBFA2T3, ETO2, 863, ENSG00000129993, ZMYND4, MTGR2, MTG16
89 results:
1. Incidence and risk factors of inguinal hernia after robot-assisted radical prostatectomy: a retrospective multicenter cohort study in Japan (the MSUG94 group).
Toide M; Ebara S; Tatenuma T; Ikehata Y; Nakayama A; Kawase M; Sasaki T; Yoneda T; Sakaguchi K; Teishima J; Makiyama K; Kitamura H; Saito K; Koie T; Inoue T; Urakami S; Koga F
J Robot Surg; 2024 Jan; 18(1):38. PubMed ID: 38231428
[TBL] [Abstract] [Full Text] [Related]
2. A machine learning radiomics model based on bpMRI to predict bone metastasis in newly diagnosed prostate cancer patients.
Xinyang S; Shuang Z; Tianci S; Xiangyu H; Yangyang W; Mengying D; Jingran Z; Feng Y
Magn Reson Imaging; 2024 Apr; 107():15-23. PubMed ID: 38181835
[TBL] [Abstract] [Full Text] [Related]
3. The association between material-psychological-behavioral framework of financial hardship and markers of inflammation: a cross-sectional study of the Midlife in the United States (MIDUS) Refresher cohort.
Surachman A; Tucker-Seeley R; Almeida DM
BMC Public Health; 2023 Sep; 23(1):1845. PubMed ID: 37735377
[TBL] [Abstract] [Full Text] [Related]
4. A blood-based metabolomic signature predictive of risk for pancreatic cancer.
Irajizad E; Kenney A; Tang T; Vykoukal J; Wu R; Murage E; Dennison JB; Sans M; Long JP; Loftus M; Chabot JA; Kluger MD; Kastrinos F; Brais L; Babic A; Jajoo K; Lee LS; Clancy TE; Ng K; Bullock A; Genkinger JM; Maitra A; Do KA; Yu B; Wolpin BM; Hanash S; Fahrmann JF
Cell Rep Med; 2023 Sep; 4(9):101194. PubMed ID: 37729870
[TBL] [Abstract] [Full Text] [Related]
5. Meta-analysis of
Yu W; Zhao M; Deng Y; Liu S; Du G; Yan B; Zhao Z; Sun N; Guo J
Cancer Imaging; 2023 Aug; 23(1):77. PubMed ID: 37605288
[TBL] [Abstract] [Full Text] [Related]
6. cancer Statistics in Pakistan From 1994 to 2021: Data From cancer Registry.
Tufail M; Wu C
JCO Clin Cancer Inform; 2023 Jul; 7():e2200142. PubMed ID: 37450777
[TBL] [Abstract] [Full Text] [Related]
7. Progressive Spreading of DNA Methylation in the GSTP1 Promoter CpG Island across Transitions from Precursors to Invasive prostate cancer.
Gupta H; Inoue H; Nakai Y; Nakayama M; Jones T; Hicks JL; Kumar B; Gurel M; Nelson WG; De Marzo AM; Yegnasubramanian S
Cancer Prev Res (Phila); 2023 Aug; 16(8):449-460. PubMed ID: 37347938
[TBL] [Abstract] [Full Text] [Related]
8. Longitudinal monitoring of Apparent Diffusion Coefficient (ADC) in patients with prostate cancer undergoing MR-guided radiotherapy on an MR-Linac at 1.5 T: a prospective feasibility study.
Almansour H; Schick F; Nachbar M; Afat S; Fritz V; Thorwarth D; Zips D; Bertram F; Müller AC; Nikolaou K; Othman AE; Wegener D
Radiol Oncol; 2023 Jun; 57(2):184-190. PubMed ID: 37341194
[TBL] [Abstract] [Full Text] [Related]
9. Development and external validation of a multivariable [
Muehlematter UJ; Schweiger L; Ferraro DA; Hermanns T; Maurer T; Heck MM; Rupp NJ; Eiber M; Rauscher I; Burger IA
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3137-3146. PubMed ID: 37261472
[TBL] [Abstract] [Full Text] [Related]
10. Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI.
Ma Z; Wang X; Zhang W; Gao K; Wang L; Qian L; Mu J; Zheng Z; Cao X
World J Surg Oncol; 2023 Mar; 21(1):83. PubMed ID: 36882854
[TBL] [Abstract] [Full Text] [Related]
11. Deep-Learning Models for Detection and Localization of Visible Clinically Significant prostate cancer on Multi-Parametric MRI.
Sun Z; Wu P; Cui Y; Liu X; Wang K; Gao G; Wang H; Zhang X; Wang X
J Magn Reson Imaging; 2023 Oct; 58(4):1067-1081. PubMed ID: 36825823
[TBL] [Abstract] [Full Text] [Related]
12. Lymphatic Dissemination in prostate cancer: Features of the Transcriptomic Profile and Prognostic Models.
Pudova EA; Kobelyatskaya AA; Katunina IV; Snezhkina AV; Fedorova MS; Pavlov VS; Bakhtogarimov IR; Lantsova MS; Kokin SP; Nyushko KM; Alekseev BY; Kalinin DV; Melnikova NV; Dmitriev AA; Krasnov GS; Kudryavtseva AV
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768739
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis.
Zhang B; Xu T
World J Surg Oncol; 2023 Jan; 21(1):2. PubMed ID: 36600256
[TBL] [Abstract] [Full Text] [Related]
14. Prevalence study of intermittent hormonal therapy of prostate cancer patients in Spain.
Bonfill-Cosp X; Auladell-Rispau A; Gich I; Zamora J; Saiz LC; Pijoan JI; Urreta I; Cordero JA
F1000Res; 2021; 10():1069. PubMed ID: 36330533
[No Abstract] [Full Text] [Related]
15. Socioeconomic inequalities in prostate cancer screening in low- and middle-income countries: An analysis of the demographic and health surveys between 2010 and 2019.
Abila DB; Wasukira SB; Ainembabazi P; Kisuza RK; Nakiyingi EK; Mustafa A; Kangoma G; Adebisi YA; Lucero-Prisno DE; Wabinga H; Niyonzima N
J Cancer Policy; 2022 Dec; 34():100360. PubMed ID: 36089226
[TBL] [Abstract] [Full Text] [Related]
16. Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.
Wrenger R; Jüptner M; Marx M; Zhao Y; Zuhayra M; Caliebe A; Osmonov D; Lützen U
BMC Urol; 2022 Jul; 22(1):96. PubMed ID: 35788220
[TBL] [Abstract] [Full Text] [Related]
17. Cost-effectiveness analysis of short biparametric magnetic resonance imaging protocol in men at risk of prostate cancer.
Faccioli N; Santi E; Foti G; Curti P; D'Onofrio M
Arch Ital Urol Androl; 2022 Jun; 94(2):160-165. PubMed ID: 35775339
[TBL] [Abstract] [Full Text] [Related]
18. Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study.
You D; Wang D; Wu Y; Chen X; Shao F; Wei Y; Zhang R; Lange T; Ma H; Xu H; Hu Z; Christiani DC; Shen H; Chen F; Zhao Y
BMC Med; 2022 Jun; 20(1):203. PubMed ID: 35658861
[TBL] [Abstract] [Full Text] [Related]
19. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
Seyrek N; Hollemans E; Andrinopoulou ER; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Remmers S; Schoots IG; van Leenders GJLH
Virchows Arch; 2022 Jun; 480(6):1149-1157. PubMed ID: 35157140
[TBL] [Abstract] [Full Text] [Related]
20. The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk prostate cancer: Results in 338 Patients Treated with Radical prostatectomy and Extended Pelvic Lymph Node Dissection.
Porcaro AB; Panunzio A; Tafuri A; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Gozzo A; Serafin E; Cianflone F; Migliorini F; Vidiri S; Di Filippo G; Novella G; Brunelli M; Shakir A; Pagliarulo V; Cerruto MA; Siracusano S; Antonelli A
Urol Int; 2022; 106(9):928-939. PubMed ID: 35081537
[TBL] [Abstract] [Full Text] [Related]
[Next]
